Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR8395] to CYP7B1
- Suitable for: WB
- Reacts with: Human
Product nameAnti-CYP7B1 antibody [EPR8395]
See all CYP7B1 primary antibodies
DescriptionRabbit monoclonal [EPR8395] to CYP7B1
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human CYP7B1 aa 400-500. The exact sequence is proprietary.
- PC3, Human fetal liver, and Human fetal kidney lysates
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Dissociation constant (KD)KD = 4.10 x 10 -11 M Learn more about KD
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab138497 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 55 kDa (predicted molecular weight: 58 kDa).|
Tissue specificityBrain, testis, ovary, prostate, liver, colon, kidney, and small intestine.
PathwayLipid metabolism; bile acid biosynthesis.
Involvement in diseaseDefects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A) [MIM:270800]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3) [MIM:613812]. Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable.
Sequence similaritiesBelongs to the cytochrome P450 family.
Cellular localizationEndoplasmic reticulum membrane. Microsome membrane.
- Information by UniProt
- 25 hydroxycholesterol 7 alpha hydroxylase antibody
- 25-hydroxycholesterol 7-alpha-hydroxylase antibody
- CP7B antibody
All lanes : Anti-CYP7B1 antibody [EPR8395] (ab138497) at 1/1000 dilution
Lane 1 : PC3 lysate
Lane 2 : Human fetal liver lysate
Lane 3 : Human fetal kidney lysate
Lysates/proteins at 30 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 58 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Equilibrium disassociation constant (KD)
Learn more about KD
Click here to learn more about KD
ab138497 has been referenced in 5 publications.
- Wei M et al. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. EBioMedicine 55:102766 (2020). PubMed: 32408110
- Huang F et al. Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat Commun 10:4971 (2019). PubMed: 31672964
- Hauser S et al. mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5. Mol Ther Methods Clin Dev 15:359-370 (2019). PubMed: 31828178
- Pathak P & Chiang JYL Sterol 12a-Hydroxylase Aggravates Dyslipidemia by Activating the Ceramide/mTORC1/SREBP-1C Pathway via FGF21 and FGF15. Gene Expr 19:161-173 (2019). PubMed: 30890204
- Donepudi AC et al. Deficiency of cholesterol 7a-hydroxylase in bile acid synthesis exacerbates alcohol-induced liver injury in mice. Hepatol Commun 2:99-112 (2018). PubMed: 29404516